LDL Apheresis in a Homozygous Familial Hypercholesterolemic Child Aged 4.5
Authors:
- 1 October 1997
- journal article
- case report
- Published by Wiley in Artificial Organs
- Vol. 21 (10) , 1126-1127
Abstract
Preliminary experience with the efficacy and safety of dextran sulfate cellulose low‐density lipoprotein (LDL) apheresis for the treatment of a 4.5‐year‐old girl with homozygous familial hypercholesterolemia and coronary artery disease is reported. The decrease of the most atherogenic apolipoprotein B‐containing lipoproteins, low‐density lipoprotein (LDL) and lipoprotein(a) (Lp [a]), were in the ranges of 63.1–68.7%, and 52.5–58.6%, respectively. The child tolerated LDL apheresis without any clinically significant complications. Therefore, she was submitted to a long‐term program of treatment at intervals of 15 days. The experience suggests the possibility of an early beginning of extracorporeal treatment with LDL apheresis in children severely affected by homozygous or double heterozygous familial hypercholesterolemia.Keywords
This publication has 7 references indexed in Scilit:
- Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemiaThe Journal of Pediatrics, 1995
- Treatment of Homozygous and Double Heterozygous Familial Hypercholesterolemia Children with LDL-ApheresisThe International Journal of Artificial Organs, 1995
- LDL‐apheresis in pediatric patients with severe hyperlipoproteinemiaJournal of Clinical Apheresis, 1995
- Treatment of children with homozygous familial hypercholesterolemia: Safety and efficacy of low-density lipoprotein apheresisThe Journal of Pediatrics, 1992
- Effect of Continuous LDL Apheresis with Dextran‐Sulfate Cellulose Column System on a Child with Homozygous Familial HypercholesterolemiaPediatrics International, 1990
- A Receptor-Mediated Pathway for Cholesterol HomeostasisScience, 1986
- Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange.BMJ, 1985